These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31237441)

  • 1. Clinical implications of mismatch repair deficiency in prostate cancer.
    Sedhom R; Antonarakis ES
    Future Oncol; 2019 Jul; 15(20):2395-2411. PubMed ID: 31237441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
    Sena LA; Fountain J; Isaacsson Velho P; Lim SJ; Wang H; Nizialek E; Rathi N; Nussenzveig R; Maughan BL; Velez MG; Ashkar R; Larson AC; Pritchard CC; Adra N; Bryce AH; Agarwal N; Pardoll DM; Eshleman JR; Lotan TL; Antonarakis ES
    Oncologist; 2021 Feb; 26(2):e270-e278. PubMed ID: 33215787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
    Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
    JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
    Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL
    Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients.
    Fang B; Wei Y; Zeng H; Li Y; Chen S; Zhang T; Pan J; Wang B; Wu J; Jin S; Gan H; Hu M; Zhang D; Ye D; Zhu Y
    Cancer Immunol Immunother; 2023 Jun; 72(6):1541-1551. PubMed ID: 36522531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
    Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS
    J Clin Invest; 2018 Oct; 128(10):4441-4453. PubMed ID: 30179225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.
    Wang T; Lee LH; Vyas M; Zhang L; Ganesh K; Firat C; Segal NH; Desai A; Hechtman JF; Ntiamoah P; Weiser MR; Markowitz AJ; Vakiani E; Klimstra DS; Stadler ZK; Shia J
    Mod Pathol; 2019 Oct; 32(10):1551-1562. PubMed ID: 31175329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
    Graham LS; Montgomery B; Cheng HH; Yu EY; Nelson PS; Pritchard C; Erickson S; Alva A; Schweizer MT
    PLoS One; 2020; 15(5):e0233260. PubMed ID: 32453797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
    Lavoie JM; Black PC; Eigl BJ
    J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of DNA mismatch repair proteins in prostate cancer.
    Sharma M; Yang Z; Miyamoto H
    Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond.
    Wong HL; Christie M; Gately L; Tie J; Lee B; Semira C; Lok SW; Wong R; Gibbs P
    Future Oncol; 2018 Nov; 14(26):2725-2739. PubMed ID: 30004261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
    Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
    Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
    Latham A; Srinivasan P; Kemel Y; Shia J; Bandlamudi C; Mandelker D; Middha S; Hechtman J; Zehir A; Dubard-Gault M; Tran C; Stewart C; Sheehan M; Penson A; DeLair D; Yaeger R; Vijai J; Mukherjee S; Galle J; Dickson MA; Janjigian Y; O'Reilly EM; Segal N; Saltz LB; Reidy-Lagunes D; Varghese AM; Bajorin D; Carlo MI; Cadoo K; Walsh MF; Weiser M; Aguilar JG; Klimstra DS; Diaz LA; Baselga J; Zhang L; Ladanyi M; Hyman DM; Solit DB; Robson ME; Taylor BS; Offit K; Berger MF; Stadler ZK
    J Clin Oncol; 2019 Feb; 37(4):286-295. PubMed ID: 30376427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
    Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
    Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
    Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry.
    Rosty C; Walsh MD; Lindor NM; Thibodeau SN; Mundt E; Gallinger S; Aronson M; Pollett A; Baron JA; Pearson S; Clendenning M; Walters RJ; Nagler BN; Crawford WJ; Young JP; Winship I; Win AK; Hopper JL; Jenkins MA; Buchanan DD
    Fam Cancer; 2014 Dec; 13(4):573-82. PubMed ID: 25117503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Testing in Prostate Cancer.
    Sokolova AO; Cheng HH
    Curr Oncol Rep; 2020 Jan; 22(1):5. PubMed ID: 31974718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.